Avanos Medical

Avanos Medical

Avanos was formed in 2018 when Kimberly-Clark spun off its health care division, Halyard Health, which then separated its surgical and infection prevention business to concentrate exclusively on medical devices. The decision left Avanos with a concentrated portfolio in two clinical verticals: chronic and post-surgical pain management, and enteral feeding systems for patients requiring nutritional support. The company is led by CEO Joe Woody, who has held the role since the spin. The firm's strategy centers on selling proprietary consumable devices and associated capital equipment directly to hospitals and ambulatory surgery centers across North America, Europe, and select Asia-Pacific markets. Its pain management line relies on non-opioid alternatives — notably the ON-Q elastomeric pump, which delivers local anesthetic to surgical sites, and the COOLIEF cooled radiofrequency system for chronic joint and nerve pain. The enteral feeding business includes the MIC-KEY low-profile gastrostomy tube and CORTRAK nasogastric tube guidance system, along with NEOMED neonatal nutrition products. Avanos does not operate as a fund or investment vehicle; its capital deployment is industrial: manufacturing capacity, new product development, and acquisitions of complementary device lines. Avanos reported roughly 3,100 employees worldwide and a commercial presence in more than 60 countries as of early 2024, with manufacturing and distribution hubs in the United States, Mexico, and Europe. The firm maintains no disclosed family-office or alternative-investment arms. Its most notable structural catalyst arrived in January 2024 when CMS implemented the NOPAIN Act, granting separate Medicare reimbursement for non-opioid pain management devices in the outpatient setting — a regulatory change that directly unblocked ON-Q and ambIT pump adoption. In July 2024, Avanos completed the sale of its respiratory health business to SunMed Group Holdings, sharpening its focus on the core pain and feeding franchises. The company's structural differentiator is its regulatory-exclusivity moat around a narrow device set that now sits outside the surgical bundled payment — a reimbursement advantage most hospital suppliers lack. Because Avanos operates as a pure-play manufacturer with no insurance, pharmacy, or facility-service lines, its P&L is exceptionally transparent to device-only utilization trends.